Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BAM 1110

Known as: BAM-1110 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
The effects of dopamine receptor agonists on urinary bladder function were evaluated in normal and 1-methyl-4-phenyl-1,2,3,6… Expand
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
1998
1998
Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.
BAM-1110 [(5R,8R,10R)-6-methyl-8-(1,2,4-triazol-l-ylmethyl) ergoline maleate] is a newly synthesized dopamine agonist that… Expand
Is this relevant?
1994
1994
Evidence for a dopamine receptor subtype sensitive to combination of D1 with D2 antagonist in measurement of G-protein activity using rat striatal membranes.
In rat striatal membranes, various kinds of dopamine receptor agonists stimulated low-Km GTPase activity in a concentration… Expand
Is this relevant?
1994
1994
Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity.
A series of new (5R,8R,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were… Expand
Is this relevant?
1988
1988
The selectivity of newly synthesized ergot derivatives to alpha 1- and alpha 2-adrenoceptors, D1- and D2-dopaminergic receptors, muscarinic acetylcholinoceptors and beta-adrenoceptors.
1. We tested affinities of newly synthesized ergot derivatives to alpha 1- and alpha 2-adrenoceptors, D1- and D2-dopamine… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE